Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

Colorectal Neoplasms --- Neoadjuvant Therapy --- Rectal Neoplasms --- Radiotherapy --- Health Care Costs --- Health Services Research --- economics --- radiotherapy --- surgery --- statistics & numerical data --- standards --- methods

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

This book contains the art and science in current standards of surgical treatment of pancreatic ductal adenocarcinoma. It explains the clinical role of surgical resection during multimodal treatment in patients with pancreatic ductal adenocarcinoma, novel surgical techniques including extended pancreatectomy and minimally invasive surgery, risk of cancer in IPMN, and the clinical importance of liquid biopsy.

Medicine --- Surgery --- unresectable pancreatic ductal adenocarcinoma --- conversion surgery --- early recurrence --- pancreatic neoplasm/analysis --- pancreatic neoplasm/surgery --- tumor location --- survival --- clinical staging --- branch duct intraductal papillary mucinous neoplasm --- risk factor --- malignancy --- meta-analysis --- laparoscopic --- pancreaticoduodenectomy --- pancreatic cancer --- borderline resectable --- neoadjuvant treatment --- chemoradiotherapy --- prognostic nutritional index --- isolated local recurrence --- pancreatectomy --- pancreatic remnant --- recurrence --- redo surgery --- pancreatic exocrine insufficiency --- adjuvant chemotherapy --- biliary drainage --- prehabilitation --- ERAS --- arterial resection --- total pancreatectomy --- neoadjuvant therapy --- pancreatic ductal adenocarcinoma --- surgical treatment --- technical advances --- pancreatic main duct dilatation --- intraductal papillary mucinous neoplasm --- high grade dysplasia --- invasive carcinoma --- pancreatic cystic neoplasm --- cell-free DNA --- mesopancreas --- superior mesenteric artery --- nerve and fibrous tissues --- lymph node dissection --- R0 resection

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

Urogenital Neoplasms --- Immunotherapy. --- Neoadjuvant Therapy. --- Genitourinary organs --- therapy. --- Cancer --- Adjuvant treatment. --- Neoadjuvant Chemoradiation --- Neoadjuvant Chemoradiation Therapy --- Neoadjuvant Chemoradiation Treatment --- Neoadjuvant Chemoradiotherapy --- Neoadjuvant Chemotherapy --- Neoadjuvant Chemotherapy Treatment --- Neoadjuvant Radiation --- Neoadjuvant Radiation Therapy --- Neoadjuvant Radiation Treatment --- Neoadjuvant Radiotherapy --- Neoadjuvant Systemic Therapy --- Neoadjuvant Systemic Treatment --- Neoadjuvant Treatment --- Chemoradiation Therapy, Neoadjuvant --- Chemoradiation Treatment, Neoadjuvant --- Chemoradiation, Neoadjuvant --- Chemoradiotherapy, Neoadjuvant --- Chemotherapy Treatment, Neoadjuvant --- Chemotherapy, Neoadjuvant --- Neoadjuvant Chemoradiation Therapies --- Neoadjuvant Chemoradiation Treatments --- Neoadjuvant Chemoradiations --- Neoadjuvant Chemoradiotherapies --- Neoadjuvant Chemotherapies --- Neoadjuvant Chemotherapy Treatments --- Neoadjuvant Radiation Therapies --- Neoadjuvant Radiation Treatments --- Neoadjuvant Radiations --- Neoadjuvant Radiotherapies --- Neoadjuvant Systemic Therapies --- Neoadjuvant Systemic Treatments --- Neoadjuvant Therapies --- Neoadjuvant Treatments --- Radiation Therapy, Neoadjuvant --- Radiation Treatment, Neoadjuvant --- Radiation, Neoadjuvant --- Radiotherapy, Neoadjuvant --- Systemic Therapy, Neoadjuvant --- Systemic Treatment, Neoadjuvant --- Therapy, Neoadjuvant --- Therapy, Neoadjuvant Chemoradiation --- Therapy, Neoadjuvant Radiation --- Therapy, Neoadjuvant Systemic --- Treatment, Neoadjuvant --- Treatment, Neoadjuvant Chemoradiation --- Treatment, Neoadjuvant Chemotherapy --- Treatment, Neoadjuvant Radiation --- Treatment, Neoadjuvant Systemic --- Immunotherapies --- Combined Antibody Therapeutics --- Immunity, Active --- Immunologic Techniques --- Càncer genitourinari --- Tractament adjuvant del càncer --- Immunoteràpia

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

Recent decades have seen remarkable advances in the treatment of upper gastrointestinal malignancies, i.e., adenocarcinoma and squamous cell carcinoma as well as gastrointestinal stromal and other rare tumors of the esophagus and stomach. While, historically, surgical resection has been the sole treatment for these tumors, multimodal therapies have meanwhile proven their efficacy. At present, pre- and postoperative chemotherapy and radiotherapy, targeted drug therapy, and stage-specific surgical approaches are all indispensable cornerstones of an individualized treatment for upper gastrointestinal malignancies. With such multimodal treatment, better outcomes comprising improved quality of life and prolonged survival have been achieved for patients. However, for many tumor entities and stages, the ideal combination and sequence of treatments is still being evaluated in clinical trials. Moreover, the value of novel approaches such as immunotherapy or robotic surgery remains a matter of research. In this Special Issue of Cancers, up-to-date original research, short communications, and comprehensive review articles on all modalities playing a role in the treatment of upper gastrointestinal malignancies have been published.

Public health & preventive medicine --- gastric cancer --- gastrectomy --- complications --- outcome --- survival --- lymph node ratio --- neoadjuvant chemotherapy --- conversion surgery --- cancer dormancy --- nuclear receptor NR2F1 --- clinical pathways --- gastric surgery --- oncological gastrectomy --- quality of care --- outcomes --- standardization --- adjuvant therapy --- gastrointestinal tract --- genetic diagnosis --- radiosensitivity --- mortality --- failure to rescue --- immunotherapy --- genetics --- esophageal cancer --- multidisciplinary --- gastric/gastroesophageal cancer --- perioperative chemotherapy --- overall survival --- relapse-free survival --- skeletal muscle index --- esophagectomy --- nutritional status --- sarcopenia --- esophageal anastomosis --- minimally invasive surgery --- induction chemotherapy --- chemo-radiotherapy --- neoadjuvant treatment --- esophageal squamous cell carcinoma --- multimodal treatment --- neoadjuvant chemoradiotherapy --- definitive chemoradiotherapy --- Lauren histotype --- gastrointestinal stromal tumor --- neuroendocrine tumor --- MALT lymphoma --- mucosal resection --- submucosal dissection --- GIST --- stomach --- neoadjuvant therapy --- imatinib --- organ preservation --- squamous cell esophageal cancer --- gastro-esophageal reflux disease --- Barrett’s esophagus --- early adenocarcinoma of esophagus --- endoscopic submucosal dissection --- endoscopic mucosal resection --- n/a --- Barrett's esophagus

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

Fibroblast growth factor (FGF) signal transmission has an essential function in embryonic development and tissue repair, and is dysregulated in the vast majority of malignancies studied. The FGF signaling in the tumor cells is usually increased by autocrine and paracrine mechanisms and gives them a high growth potential, resistance to apoptosis, neoangiogenesis and metastasis, all essential parameters relevant for tumor progression. This makes FGFs, and their tyrosine kinase receptors FGFRs, valuable targets for therapeutic interventions. This book is a collection of 15 recent articles—both original work and reviews—that summarize the current research state effectively. The content covers FGF signaling aspects in gastric, skin, liver, esophageal cancer, melanoma, mesothelioma and glioblastoma, including one article that addresses the role of FGF in the tumor-microenvironment cross-talk. Several reports describe the development of compounds targeting FGFRs, their structure and interaction with the receptor molecules, and their effectivity in preclinical and clinical testing. In summary, the papers demonstrate the complexity of the topic, with various FGF ligands and receptors involved and the need for further research. They also present results that fuel hope that targeting cancer with dysfunctional FGF signaling can become a realistic treatment option.

FGFR4 --- FGF19 --- gene regulation --- cancer signaling --- anticancer --- FRS2 --- FGFR --- NVP-BGJ398 --- LY2874455 --- sarcoma --- cancer-associated fibroblasts --- GPER --- breast cancer --- estrogen --- FGFR1 --- FGF2 --- optogenetics --- ERK --- AKT --- receptor kinase --- neurite outgrowth --- HEK293 --- PC12 --- fibroblast growth factor receptors --- signaling --- receptor cross-talk --- coreceptor --- membrane proteins --- FGFR2 --- ERK1/2 --- phosphorylation --- serine --- negative feedback loop --- cancer --- prognosis --- HCC --- inhibitors --- FGF --- fibroblast growth factor --- autocrine signaling --- skin --- melanoma --- squamous and basal cell carcinoma --- seborrheic keratosis --- targeted therapy --- resistance --- structure --- kinase inhibitor --- gastric cancer --- monoclonal antibody --- small molecule --- FGFR2c --- autophagy --- keratinocyte --- MTOR --- JNK1 --- review --- malignant glioma --- brain cancer --- astrocytoma --- Sprouty proteins --- FGF-mediated signaling --- tumor suppressor --- tumor promoter --- malignant pleural mesothelioma --- overall survival --- immunohistochemistry --- infigratinib sensitivity --- FGF8 --- FGF18 --- adenocarcinoma of the esophagogastric junction --- neoadjuvant therapy --- n/a